131I
The appearance of fatigue, drowsiness, increased body mass, chills, convulsions, increased menstrual flow and constipation in young and middle-aged women after treatment suggests the possibility of early onset hypothyroidism and should be reviewed promptly. Thyroid hormone levels are below the normal range, even if
If TSH is still suppressed, early onset hypothyroidism should be considered. Replacement therapy with levothyroxine sodium or thyroid tablets may be indicated after the onset of hypothyroidism. The timing of replacement therapy depends on thyroid function tests, clinical symptoms and physical examination findings. The dosage should be adjusted under the guidance of a physician to maintain normal thyroid hormone levels, and regular follow-up examinations should be insisted upon during replacement therapy. For patients with Graves’ hyperthyroidism who are not in remission and have poor efficacy after 3-6 months of 131I treatment, re-treatment with 131I may be recommended according to the needs of the patient.
treatment. The dose of 131I may be increased for patients with ineffective or aggravated treatment and complications. A small number of patients with large, hard thyroid glands require multiple 131I
treatment to achieve complete remission. Surgery may be recommended for a small number of patients with refractory Graves’ hyperthyroidism who have failed to respond to repeated 131I therapy or who have relapsed. For patients with persistent TSH suppression and normal TT3 and
FT4 are normal, regular monitoring is required to prevent the reappearance of clinical hyperthyroidism or hypothyroidism.